witty

GSK CEO Andrew Witty on “Exploring Delinking the R&D Charge”

At a March 17, 2016, Center for Strategic and International Studies (CSIS) event in Washington, D.C., on “The Bio-Pharma Industry and Society,” Sir Andrew Witty’s keynote address included a discussion of GSK’s decision to explore the delinkage of R&D costs from drug prices. Witty suggested that delinkage could initially be implemented in the context of Read more about GSK CEO Andrew Witty on “Exploring Delinking the R&D Charge”[…]